606 completed. 606 Phase 2, 95 Phase 1, 86 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 606 | Completed 606 |
| Phase 1 | 95 | Completed 95 |
| Phase 3 | 86 | Completed 86 |
Follow Overweight: new trials by email Literature Review of Overweight trials Research Report on Overweight
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dietary Interventions to Reduce Ultra-Processed Food Intake Introductory Educational Workshop, Standard Dietary Change (ON/OFF), Cognitive Dissonance Strategies (ON/OFF) - Ultra-Processed Food Intake, Obesity & Overweight | Phase 2 | Completed | Oregon Research Institute | 59 | 2026-02-10 | 2026-10-15 |
| Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity MWN109 1, MWN109 2, MWN109 3 - Overweight , Obesity | Phase 2 | Completed | Shanghai Minwei Biotechnology Co., Ltd | 255 | 2026-01-05 | 2026-08-28 |
| Aleniglipron Phase 2 in Type 2 Diabetes Mellitus Aleniglipron, Placebo - Obese, Obesity | Phase 2 | Completed | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 58 | 2025-12-01 | 2026-10-21 |
| A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities VRB-101, Placebo - Obesity, Overweight | Phase 2 | Completed | Verdiva Bio Dev Limited | 206 | 2025-11-25 | 2026-08-17 |
| Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV Tirzepatide - Obesity and Overweight, HIV | Phase 2 | Completed | University of Hawaii | 12 | 2025-11-12 | 2026-07-08 |
| Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) NT-0796, Placebo - Obesity | Phase 2 | Completed | Rezera (formerly NodThera Limited) | 82 | 2025-10-02 | 2026-10-27 |
| Phase 2 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity MWN105 1, MWN105 2, MWN105 3 - Overweight , Obesity | Phase 2 | Completed | Shanghai Minwei Biotechnology Co., Ltd | 120 | 2025-09-03 | 2026-09-04 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or Obesity MWN109 1, MWN109 2, MWN109 3 - Overweight , Obesity | Phase 2 | Completed | Shanghai Minwei Biotechnology Co., Ltd | 120 | 2025-08-23 | 2026-08-28 |
| Aleniglipron Phase 2 Body Composition Study aleniglipron or placebo - Obesity, Overweight, or Chronic Weight Management | Phase 2 | Completed | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 71 | 2025-08-15 | 2026-10-14 |
| A Study Evaluating the Effect of Daily Oral Tifeglipron (RO7795081) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Tifeglipron, Placebo - Obesity or Overweight | Phase 2 | Completed | Hoffmann-La Roche | 352 | 2025-07-29 | 2026-11-12 |
| A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants CX11, Placebo - Obesity | Phase 2 | Completed | Corxel Pharmaceuticals | 250 | 2025-06-17 | 2026-05-28 |
| RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight Pemvidutide, Placebo - Alcohol Use Disorder (AUD) | Phase 2 | Completed | Altimmune, Inc. | 100 | 2025-05-15 | 2026-07-31 |
| A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects DA-302168S, Placebo of DA-302168S - Overweight and Obesity | Phase 2 | Completed | Chendu DIAO Pharmaceutical Group CO., LTD. | 250 | 2025-05-15 | 2026-05-28 |
| Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus NT-0796, Placebo - Obesity and Type 2 Diabetes | Phase 2 | Completed | Rezera (formerly NodThera Limited) | 176 | 2025-05-08 | 2026-09-15 |
| Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) Petrelintide, Placebo - Overweight, Type 2 Diabetes | Phase 2 | Completed | Zealand Pharma | 221 | 2025-04-22 | 2026-09-09 |
| A Study of BGM0504 in Participants With Obesity BGM0504, Tirzepatide - Obesity | Phase 2 | Completed | BrightGene Bio-Medical Technology Co., Ltd. | 96 | 2025-04-09 | 2026-10-13 |
| A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight MET097, Placebo - Obesity, Overweight or Obesity | Phase 2 | Completed | Pfizer | 268 | 2025-04-07 | 2026-11-05 |
| Effect of Tirzepatide on Brown Adipose Tissue in Obesity Tirzepatide, Placebo - Obesity | Phase 2 | Completed | University Medical Centre Ljubljana | 34 | 2025-03-18 | 2026-07-07 |
| A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM MET097 Injection, Placebo - Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM) | Phase 2 | Completed | Pfizer | 133 | 2025-03-14 | 2026-06-12 |
| UBT251 Injection Phase II Study (Overweight or Obesity) UBT251 Injection 2.0 mg and UBT251 Injection Placebo, UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo, UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo - Obesity &Amp; Overweight | Phase 2 | Completed | The United Bio-Technology (Hengqin) Co., Ltd. | 205 | 2025-03-14 | 2026-11-05 |
Showing 20 of 606. Sign in to see all of them.
Obesity (526) · Weight Loss (68) · Diabetes Mellitus, Type 2 (60) · Insulin Resistance (54) · Diabetes Mellitus (44) · Metabolic Syndrome (41) · Motor Activity (33) · Hypertension (25) · Obesity, Abdominal (20) · Obesity, Morbid (18) · Glucose Intolerance (17) · Non-alcoholic Fatty Liver Disease (17) · Pediatric Obesity (17) · Prader-Willi Syndrome (17)
Nutritional and Metabolic Diseases (604) · Overnutrition (602) · Nutrition Disorders (600) · Pathological Conditions, Signs and Symptoms (595) · Signs and Symptoms (592) · Body Weight (576) · Metabolic Diseases (166) · Glucose Metabolism Disorders (164) · Endocrine System Diseases (109) · Hyperinsulinism (77) · Body Weight Changes (73) · Diabetes Mellitus (58) · Obesity (53) · Behavior (47)
Exercise (19) · Metformin (16) · semaglutide (15) · Liraglutide (13) · Diet (11) · Tirzepatide (10) · Topiramate (10) · Exenatide (9) · Oxytocin (8) · bupropion hydrochloride, naltrexone hydrochoride drug combination (8) · metreleptin (8) · pramlintide (7) · Orlistat (6) · Phentermine (6) · Sodium Chloride (6)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (18) · AstraZeneca (13) · Eli Lilly and Company (10) · Yale University (10) · Mayo Clinic (9) · Pfizer (9) · University of Minnesota (9) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (8) · University of Pittsburgh (8) · Vanderbilt University Medical Center (8) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (7) · Massachusetts General Hospital (7) · Merck Sharp & Dohme LLC (7) · Novartis Pharmaceuticals (7) · Novo Nordisk A/S (7)
United States (364) · Canada (43) · China (29) · United Kingdom (27) · France (24) · Netherlands (19) · Australia (18) · Denmark (18) · Germany (17) · Spain (17) · Sweden (17) · Mexico (12) · Japan (11) · Finland (10) · Poland (8)
Jack A Yanovski, M.D. (8) · John M Jakicic, Ph.D. (5) · Lisa Porter, MD (5) · Allison B. Goldfine, MD (4) · David Meeker, MD (4) · Frank Greenway, MD (3)
PMID 23703580, PMID 26210388, PMID 26589105, PMID 12150647, PMID 18753666, PMID 19741604, PMID 19889232, PMID 21070531, PMID 21720440, PMID 21816979, PMID 25091629, PMID 28059466, PMID 29718281, PMID 33029899, PMID 35112343, PMID 38365073, PMID 42014131, PMID 10480510, PMID 10523015, PMID 10868854, PMID 10963727, PMID 11411567, PMID 11443202, PMID 11556815, PMID 12105286, PMID 12126214, PMID 12523673, PMID 12622244, PMID 12805393, PMID 12833109, PMID 15070752, PMID 15112907, PMID 15168555, PMID 15333514, PMID 15570151, PMID 15698985, PMID 15713712, PMID 15899688, PMID 15949871, PMID 16054141, PMID 16294118, PMID 16397156, PMID 16397157, PMID 16397158, PMID 16397159, PMID 16397160, PMID 16397161, PMID 16397162, PMID 16626303, PMID 16672847
2017 (6), 2009 (5), 2023 (4), 2008 (3), R01DK049587 (3), R01DK126637 (3), 2014 (2), 2015 (2), 2016 (2), R56DK067071 (2), U01CA150387 (2), U01DK074556 (2), UL1TR000135 (2), 2004 (1), 2018 (1)